What is Catalym Gmbh's official website?

Catalym Gmbh's website is catalym.com

What is Catalym Gmbh's industry?

Catalym Gmbh's industry is Biotechnology Research

Who are Catalym Gmbh's top competitors?

Catalym Gmbh's top competitors are , , , , , ,

Catalym Gmbh company information, Employees & Contact Information

Explore related pages

Catalym Gmbh email format Catalym Gmbh management contacts

Related company profiles:

External link for CatalYm GmbH

Employees: 63
Address: Am Klopferspitz 19, Martinsried,bayern 82152,germany
Phone: 1844 66 34837
Industry: Biotechnology Research
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)
Website: catalym.com
Keywords: in oncology and partnering will be a substantial asset as we initiate a broad Phase 2b program with our lead candidate.
HQ: Martinsried, Bayern
Competitors: MorphoSys, Tubulis GmbH, PROTEROS biostructures GmbH, SURGE Therapeutics, Scorpion Therapeutics, Medigene AG, iOmx Therapeutics AG, Cardurion Pharmaceuticals, SciRhom, Eisbach Bio GmbH.

Catalym Gmbh Questions

News

CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development - Business Wire

CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development Business Wire

CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025 - The AI Journal

CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025 The AI Journal

CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO - Yahoo Finance

CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO Yahoo Finance

Eugen Leo: Advancing Cancer Care – Tackling Cachexia and Tumor Resistance - Oncodaily

Eugen Leo: Advancing Cancer Care – Tackling Cachexia and Tumor Resistance Oncodaily

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC - Yahoo Finance

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC Yahoo Finance

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab - FinancialContent

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab FinancialContent

CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature - Business Wire

CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature Business Wire

CatalYm taps 4 industry vets, lets go of 3 leaders in C-suite change-up - Fierce Biotech

CatalYm taps 4 industry vets, lets go of 3 leaders in C-suite change-up Fierce Biotech

CatalYm joins Pfizer in pivotal cachexia push | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

CatalYm joins Pfizer in pivotal cachexia push | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

GDF-15 blockade: A multi-directional approach to potentiate cancer immunotherapy and alleviate cancer cachexia - Wiley Online Library

GDF-15 blockade: A multi-directional approach to potentiate cancer immunotherapy and alleviate cancer cachexia Wiley Online Library

New quartet brings decades of industry experience to CatalYm - The Pharma Letter

New quartet brings decades of industry experience to CatalYm The Pharma Letter

CatalYm publishes data in Nature Communications describing gdf-15 as a central factor of anti-PD-1 resistance - EurekAlert!

CatalYm publishes data in Nature Communications describing gdf-15 as a central factor of anti-PD-1 resistance EurekAlert!

German biotech CatalYm cashes in on early-stage cancer data with $150M series D - Fierce Biotech

German biotech CatalYm cashes in on early-stage cancer data with $150M series D Fierce Biotech

CatalYm appoints Scott Clarke as CEO - The Pharma Letter

CatalYm appoints Scott Clarke as CEO The Pharma Letter

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab - Business Wire

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab Business Wire

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO - Yahoo Finance

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO Yahoo Finance

Chutes & Ladders—CatalYm catalyzes C-suite shake-up - Fierce Biotech

Chutes & Ladders—CatalYm catalyzes C-suite shake-up Fierce Biotech

CatalYm gaining momentum with GDF-15 neutralizing approach - The Pharma Letter

CatalYm gaining momentum with GDF-15 neutralizing approach The Pharma Letter

CatalYm shows potential of visugromab for treating cachexia - PharmaTimes

CatalYm shows potential of visugromab for treating cachexia PharmaTimes

Catalym raises US$150m - European Biotechnology Magazine

Catalym raises US$150m European Biotechnology Magazine

(PDF) Neutralizing GDF-15 can overcome anti-PD-(L)1 resistance in late-stage cancer - researchgate.net

(PDF) Neutralizing GDF-15 can overcome anti-PD-(L)1 resistance in late-stage cancer researchgate.net

CatalYm - The Pharma Letter

CatalYm The Pharma Letter

Oklahoma City News - The Oklahoman - FinancialContent

Oklahoma City News - The Oklahoman FinancialContent

CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation - FinancialContent

CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation FinancialContent

CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort - FinancialContent

CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort FinancialContent

Companies like Catalym Gmbh

Top Catalym Gmbh Employees

Dr.Aradhana Dutta

Pharmacovigilance Physician / Oncology Early Phase

N/a

View
Marianne Uteng

Managing Director At Novartis Venture Fund

N/a

View
Anne Burger

n/a

Germany, Germany

View

1
medventurepartners.com
Petra Fettes

Senior Vice President, Head Clinical Operations At Catalym Gmbh

Greater Munich Metropolitan Area, Germany, Germany

View

4
web.de, amgen.com, isarna-therapeutics.com, catalym.com

3 +164667XXXXX

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Catalym Gmbh company information, Employees & Contact Information

Explore related pages

Company Details

Catalym Gmbh Questions

What is Catalym Gmbh's helpline number?

What is Catalym Gmbh's official website?

What is Catalym Gmbh's LinkedIn profile?

How many employees are working in Catalym Gmbh right now?

What is Catalym Gmbh's industry?

What are Catalym Gmbh's top competitors?

What are Catalym Gmbh's categories?

News

CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development - Business Wire

CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025 - The AI Journal

CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO - Yahoo Finance

Eugen Leo: Advancing Cancer Care – Tackling Cachexia and Tumor Resistance - Oncodaily

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC - Yahoo Finance

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab - FinancialContent

CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature - Business Wire

CatalYm taps 4 industry vets, lets go of 3 leaders in C-suite change-up - Fierce Biotech

CatalYm joins Pfizer in pivotal cachexia push | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

GDF-15 blockade: A multi-directional approach to potentiate cancer immunotherapy and alleviate cancer cachexia - Wiley Online Library

New quartet brings decades of industry experience to CatalYm - The Pharma Letter

CatalYm publishes data in Nature Communications describing gdf-15 as a central factor of anti-PD-1 resistance - EurekAlert!

German biotech CatalYm cashes in on early-stage cancer data with $150M series D - Fierce Biotech

CatalYm appoints Scott Clarke as CEO - The Pharma Letter

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab - Business Wire

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO - Yahoo Finance

Chutes & Ladders—CatalYm catalyzes C-suite shake-up - Fierce Biotech

CatalYm gaining momentum with GDF-15 neutralizing approach - The Pharma Letter

CatalYm shows potential of visugromab for treating cachexia - PharmaTimes

Catalym raises US$150m - European Biotechnology Magazine

(PDF) Neutralizing GDF-15 can overcome anti-PD-(L)1 resistance in late-stage cancer - researchgate.net

CatalYm - The Pharma Letter

Oklahoma City News - The Oklahoman - FinancialContent

CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation - FinancialContent

CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort - FinancialContent

Companies like Catalym Gmbh

Scirhom

Eisbach Bio Gmbh

Medigene Ag

Tubulis Gmbh

Iomx Therapeutics Ag

Surge Therapeutics

Proteros Biostructur...

Cardurion Pharmaceut...

Morphosys

Scorpion Therapeutics

Top Catalym Gmbh Employees

Dr.Aradhana Dutta

Pharmacovigilance Physician / Oncology Early Phase

Marianne Uteng

Managing Director At Novartis Venture Fund

Anne Burger

n/a

Petra Fettes

Senior Vice President, Head Clinical Operations At Catalym Gmbh

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data